EP4251633A4 - Cd73-inhibitoren und pharmazeutische verwendungen davon - Google Patents
Cd73-inhibitoren und pharmazeutische verwendungen davon Download PDFInfo
- Publication number
- EP4251633A4 EP4251633A4 EP21896011.0A EP21896011A EP4251633A4 EP 4251633 A4 EP4251633 A4 EP 4251633A4 EP 21896011 A EP21896011 A EP 21896011A EP 4251633 A4 EP4251633 A4 EP 4251633A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- inhibitors
- pharmaceutical uses
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011346141 | 2020-11-25 | ||
| US17/133,348 US11530234B2 (en) | 2018-09-11 | 2020-12-23 | CD73 inhibitors and pharmaceutical uses thereof |
| PCT/CA2021/051688 WO2022109741A1 (en) | 2020-11-25 | 2021-11-25 | Cd73 inhibitors and pharmaceutical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4251633A1 EP4251633A1 (de) | 2023-10-04 |
| EP4251633A4 true EP4251633A4 (de) | 2024-09-25 |
Family
ID=81753702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21896011.0A Pending EP4251633A4 (de) | 2020-11-25 | 2021-11-25 | Cd73-inhibitoren und pharmazeutische verwendungen davon |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4251633A4 (de) |
| CN (1) | CN116546990A (de) |
| AU (1) | AU2021389685A1 (de) |
| CA (1) | CA3200232A1 (de) |
| WO (1) | WO2022109741A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025260011A1 (en) * | 2024-06-14 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | 5'-modified monomers, oligonucleotides and double-stranded rnas |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200078388A1 (en) * | 2018-09-11 | 2020-03-12 | Risen (Suzhou) Pharma Tech Co. Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
| WO2020051686A1 (en) * | 2018-09-11 | 2020-03-19 | Risen (Suzhou) Pharma Tech Co. Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3399984T3 (da) * | 2016-01-08 | 2023-11-13 | Arcus Biosciences Inc | Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf |
| CN114539340B (zh) * | 2020-11-25 | 2024-06-07 | 润佳(苏州)医药科技有限公司 | Cd73抑制剂及其药学应用 |
-
2021
- 2021-11-25 WO PCT/CA2021/051688 patent/WO2022109741A1/en not_active Ceased
- 2021-11-25 CN CN202180079532.7A patent/CN116546990A/zh active Pending
- 2021-11-25 CA CA3200232A patent/CA3200232A1/en active Pending
- 2021-11-25 AU AU2021389685A patent/AU2021389685A1/en active Pending
- 2021-11-25 EP EP21896011.0A patent/EP4251633A4/de active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200078388A1 (en) * | 2018-09-11 | 2020-03-12 | Risen (Suzhou) Pharma Tech Co. Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
| WO2020051686A1 (en) * | 2018-09-11 | 2020-03-19 | Risen (Suzhou) Pharma Tech Co. Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2022109741A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3200232A1 (en) | 2022-06-02 |
| AU2021389685A9 (en) | 2024-02-08 |
| AU2021389685A1 (en) | 2023-07-06 |
| EP4251633A1 (de) | 2023-10-04 |
| WO2022109741A1 (en) | 2022-06-02 |
| CN116546990A (zh) | 2023-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4215208A4 (de) | Pharmazeutische kombination und verwendung davon | |
| EP3849992A4 (de) | Cd73-inhibitoren und ihre pharmazeutischen verwendungen | |
| EP4129283A4 (de) | Pharmazeutische kombination und verwendung davon | |
| CA3265870A1 (en) | Pharmaceutical compositions based on topoisomerase-1 inhibitors derived from Exatecan, and their uses | |
| EP3960741A4 (de) | Chinolinverbindungen und pharmazeutische zusammensetzungen und deren verwendungen | |
| EP3843742A4 (de) | Cd73-inhibitoren und deren therapeutische verwendungen | |
| EP4251633A4 (de) | Cd73-inhibitoren und pharmazeutische verwendungen davon | |
| EP4330228A4 (de) | G-alpha-s-hemmer und verwendungen davon | |
| EP4364735A4 (de) | Pharmazeutische zusammensetzung und verwendung davon | |
| EP4319740A4 (de) | Urat1-inhibitor, pharmazeutische zusammensetzungen und verwendungen davon | |
| EP4342492A4 (de) | Pharmazeutische kombination und verwendung davon | |
| EP4129282A4 (de) | Pharmazeutische kombination und verwendung davon | |
| EP3967693A4 (de) | Amorpher pi3k-inhibitor und diesen enthaltende pharmazeutische zusammensetzung | |
| HK40076361A (en) | Aspacytarabine pharmaceutical compositions and uses thereof | |
| EP4100020A4 (de) | Pharmazeutische aspacytarabinzusammensetzungen und verwendungen davon | |
| HK40108347A (en) | Inhibitors and uses thereof | |
| HK40107944A (en) | Urat1 inhibitor, pharmaceutical compositions and uses thereof | |
| EP4125873A4 (de) | Pharmazeutische zusammensetzungen und verwendung davon | |
| HK40085903A (en) | Zbtb32 inhibitors and uses thereof | |
| HK40099664A (en) | Pharmaceutical composition and use thereof | |
| HK40082856A (en) | Inhibitors and uses thereof | |
| HK40111933A (en) | Rock2 inhibitors and uses thereof | |
| HK40105811A (en) | Tyk2 inhibitors and uses thereof | |
| HK40105297A (zh) | Tyk2抑制剂及其用途 | |
| HK40105803A (en) | Tyk2 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230623 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240822 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20240817BHEP Ipc: A61K 31/7076 20060101ALI20240817BHEP Ipc: A61K 45/06 20060101ALI20240817BHEP Ipc: C07H 19/20 20060101AFI20240817BHEP |
|
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RISEN (SUZHOU) PHARMA TECH CO., LTD. |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |